Clinical trials: Monoclonal Antibody
Crohn's Disease
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
- Trial name
- CHARM (NCT00077779)
- Testing
- Adalimumab
- Where
- 43 sites in United States
- Volunteers
- 854 people
- Sponsor
- Abbott
HIV Infections
The Safety and Effectiveness of Human Monoclonal Antibody, F105, in the Treatment of HIV
To determine the safety and pharmacokinetics of F105 human monoclonal antibody both following a single dose and during intermittent administration in HIV-infected patients.
- Trial name
- NCT00001105
- Testing
- F105 Monoclonal Antibody (Human)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Newly Diagnosed Multiple Myeloma (NDMM)
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
To conduct a multicenter, prospective observational cohort study to investigate first-line immunotherapy patterns and clinical outcomes in NDMM patients in China.
- Trial name
- PRIMARY (NCT07296627)
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Peking University People's Hospital
Systemic Lupus Erythematosus
Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects
The study is an open-labeled extension study to continue to assess the safety and tolerability of Epratuzumab in moderate to severe SLE subjects who have previously participated in SL0026 [NCT01449071] phase I/II trial.
- Trial name
- NCT01534403
- Testing
- Epratuzumab
- Where
- 6 sites in Japan
- Volunteers
- 17 people
- Sponsor
- UCB Pharma
Osteoarthritis, Knee
Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain
The purpose of this study is to evaluate the safety and tolerability of a single intravenous dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring substance, nerve growth factor (NGF).
- Trial name
- NCT00941746
- Testing
- PG110
- Where
- Netherlands
- Volunteers
- 56 people
- Sponsor
- Abbott
Solid Tumor of Epithelial Origin, Gastric Cancer
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors
The purpose of this study is to determine the safety and tolerability profile including the dose limiting toxicity of AbGn-7 in patients with chemo-refractory advanced solid tumor of epithelial origin, and of AbGn-7 in…
- Trial name
- NCT01466569
- Testing
- AbGn-7
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 13 people
- Sponsor
- AbGenomics B.V Taiwan Branch
Homozygous Familial Hypercholesterolemia
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia
A study to evaluate safety and efficacy of IBI306 in subjects with homozygous familial hypercholesterolemia.
- Trial name
- NCT04031742
- Testing
- IBI306
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Chronic Lymphocytic Leukemia
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia
RATIONALE: Monoclonal antibodies, such as rituximab and alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT01013961
- Testing
- alemtuzumab, rituximab
- Where
- 102 sites in United States
- Volunteers
- 31 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Bladder Cancer
Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer
The purpose of this study is to find out the highest safe dose of the investigational drug CP-675,206 when given in combination with BCG therapy to patients who have experienced recurrent superficial bladder cancer after standard…
- Trial name
- NCT00880854
- Testing
- BCG and CP-675,206
- Sponsor
- University of Wisconsin, Madison
COVID
COVID-19 : Neutralizing Human Monoclonal Antibodies Against SARS-Cov-2
Rationale : The emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) threatens public health. To date, there are no effective drug option to prevent the infection, nor therapeutics for controlling the deadly…
- Trial name
- ANTI-COV-2 (NCT04354766)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Hospices Civils de Lyon
High Frequency Episodic Migraine and Chronic Migraine
"Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment"
Migraine, a complex and multifaceted disorder, remains only partially understood, with therapeutic strategies often limited by individual variability in response.
- Trial name
- NCT06692088
- Volunteers
- 216 people, healthy volunteers welcome
- Sponsor
- Fundación Marques de Valdecilla
Neoplasms, Solid Tumors
ADC-1013 First-in-Human Study
The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or…
- Trial name
- NCT02379741
- Testing
- ADC-1013
- Where
- 5 sites in Denmark, Sweden and 1 more
- Volunteers
- 24 people
- Sponsor
- Alligator Bioscience AB
Crohn's Disease, Colitis
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn's Disease
The purpose of the HARMONY study is to assess the safety and efficacy of an investigational drug called HuZAF, in patients with moderate to severe Crohn's disease (CD).
- Conditions
- Crohn's Disease, Colitis, Intestinal Disease, Gastrointestinal Disease
- Trial name
- NCT00072943
- Testing
- anti-Interferon-gamma monoclonal antibody
- Where
- 19 sites in United States, Canada
- Volunteers
- 175 people
- Sponsor
- Facet Biotech
Pre-cancerous Lymphoproliferative Disorders
Oxford Pre-cancerous Lymphoproliferative Disorders Study
OxPLoreD is an observational cohort study to identify clinical, genomic and immunological predictive markers of progression to malignant disease.
- Trial name
- OxPLoreD (NCT04023747)
- Where
- 17 sites in United Kingdom
- Volunteers
- 574 people
- Sponsor
- University of Oxford
Lupus Erythematosus, Systemic
Synergetic B-cell Immodulation in SLE
The present study investigates the potential of a new therapeutic approach in lupus nephritis combining rituximab (anti-CD20) and belimumab (anti-BAFF).
- Trial name
- SYNBIoSe (NCT02284984)
- Testing
- Rituximab with belimumab
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- Leiden University Medical Center
Relapsed Small Cell Lung Cancer
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients
- Trial name
- NCT04421352
- Testing
- CS1001
- Where
- China
- Volunteers
- 11 people
- Sponsor
- CStone Pharmaceuticals
Advanced Lung Cancer
WTX212A Monotherapy and in Combination With PD -1/PD-L1 Monoclonal Antibody
This trial is a single-center, open-label designed investigator-initiated clinical study (IIT) to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of WTX212A injection WTX212A injection combined with PD…
- Trial name
- NCT06106152
- Testing
- WTX212A injection, PD -1/PD-L1 monoclonal antibody
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057889
- Testing
- ipilimumab
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Congenital Heart Disease
A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
The primary goal was to describe the safety of the investigational product when given monthly to prevent serious respiratory infection among children with significant heart disease.
- Trial name
- NCT00538785
- Testing
- Motavizumab, Palivizumab
- Where
- 152 sites in United States, Austria and 15 more
- Volunteers
- 1,236 people
- Sponsor
- MedImmune LLC
Severe Crohn's Disease, Anxiety
Reveal the Level of Anxiety in Patients With Crohn's Disease Receiving Adalimumab
It has been shown that emotional health issues, such as state anxiety, are more prevalent in patients suffering from inflammatory bowel disease (IBD) compared to physically healthy subjects.
- Trial name
- RELAX (NCT01428115)
- Where
- 8 sites in Austria
- Volunteers
- 83 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.